Immune-based treatment and prevention of Clostridium difficile infection

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 12, 2014, Pages 3522-3530

  Zhao, Song ^a,b   Ghose Paul, Chandrabali ^c   Zhang, Keshan ^a   Tzipori, Saul ^a   Sun, Xingmin ^a,d  

^a TUFTS UNIVERSITY   (United States)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

Bacterial toxins; Clostridium difficile infection (CDI); Immunotherapy; Monoclonal antibody; Vaccine

Indexed keywords

BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN B ANTIBODY; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; ULOCUPLUMAB; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE RE-EMERGENCE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; ANIMAL; BLOOD; CLOSTRIDIUM INFECTIONS; IMMUNOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ANIMALS; ANTIBODIES, BACTERIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY;

EID: 84922540799     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.980193     Document Type: Review

References (110)

1. Songer JG. Clostridial enteric diseases of domestic animals. Clin Microbiol Rev 1996; 9:216-34; PMID:8964036
2. Keel MK, Songer JG. The comparative pathology of Clostridium difficile-associated disease. Vet Pathol 2006; 43:225-40; PMID:16672570; http://dx.doi.org/10.1354/vp.43-3-225
3. Richardson SA, Alcock PA, Gray J. Clostridium difficile and its toxin in healthy neonates. Brit Med J 1983; 287:878; PMID:6412868; http://dx.doi.org/10.1136/bmj.287.6396.878
4. INTESTINAL flora of infants. Nutr Rev 1952; 10:198-9; PMID:14957293
5. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-36; PMID:19528959; http://dx.doi.org/10.1038/nrmicro2164
6. Kelly CP, La Mont JT. Clostridium difficile infection. Annu Rev Med 1998; 49:375-90; PMID:9509270; http://dx.doi.org/10.1146/annurev.med.49.1.375
7. Zar F, Bakkanagari S, Moorthi KMLST, Davis M. A comparison of vancomycin and metronidazole for the treatment of clostridium difficileâ€"associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7; PMID:17599306; http://dx.doi.org/10.1086/519265
8. Koo HL, Garey KW, Dupont HL. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Invest Drugs 2010; 19:825-36; PMID:20521993; http://dx.doi.org/10.1517/13543784.2010.495386
9. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2386-8; PMID:10835010
10. Tonna I, Welsby PD. Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J 2005; 81:367-9; PMID:15937201[http://dx.doi.org/10.1136/pgmj.2004.028480
11. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002; PMID:22002980; http://dx.doi.org/10.1093/cid/cir632
12. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010; 44:354-60; PMID:20048681
13. Senior K. Faecal transplantation for recurrent C difficile diarrhoea. Lancet Infect Dis 2013; 13:200-1; PMID:23550305; http://dx.doi.org/10.1016/S1473-3099(13)70052-5
14. Suwantarat N, Bobak DA. Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection. Curr Infect Dis Rep 2011; 13:21-7; PMID:21308451; http://dx.doi.org/10.1007/s11908-010-0155-7
15. Barra-Carrasco J, Paredes-Sabja D. Clostridium difficile spores: a major threat to the hospital environment. Fut Microbiol 2014; 9:475-86; PMID:24810347; http://dx.doi.org/10.2217/fmb.14.2
16. Weber DJ, Anderson DJ, Sexton DJ, Rutala WA. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control 2013; 41:S105-10; PMID:23622740; http://dx.doi.org/10.1016/j.ajic.2012.12.009
17. Hoover DG, Rodriguez-Palacios A. Transmission of Clostridium difficile in foods. Infect Dis Clin N Am 2013; 27:675-85; PMID:24011836; http://dx.doi.org/10.1016/j.idc.2013.05.004
18. Harbarth S, Samore MH. Clostridium: transmission difficile? PLoS Med 2012; 9:e1001171; PMID:22346737; http://dx.doi.org/10.1371/journal. pmed.1001171
19. Hopman NE, Sanders IM, Kuijper EJ, Lipman LJ. Low risk of transmission of Clostridium difficile to humans at petting farms. Vet Microbiol 2011; 150:416-7; PMID:21411249; http://dx.doi.org/10.1016/j.vetmic.2011.02.015
20. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 2012; 20:313-9; PMID:22595318; http://dx.doi.org/10.1016/j. tim.2012.04.001
21. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by clostridium difficle. Gastroenterology 2014; 146:1547-53; PMID:24503131; http://dx.doi.org/10.1053/j. gastro.2014.01.059
22. Janoir C, Pechine S, Grosdidier C, Collignon A. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J Bacteriol 2007; 189:7174-80; PMID:17693508; http://dx.doi.org/10.1128/JB.00578-07
23. Calabi E, Ward S, Wren B, Paxton T, Panico M, Morris H, Dell A, Dougan G, Fairweather N. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol 2001; 40:1187-99; PMID:11401722; http://dx.doi.org/10.1046/j.1365-2958.2001.02461.x
24. Waligora AJ, Hennequin C, Mullany P, Bourlioux P, Collignon A, Karjalainen T. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun 2001; 69:2144-53; PMID:11254569; http://dx.doi.org/10.1128/IAI.69. 4.2144-2153.2001
25. Hennequin C, Porcheray F, Waligora-Dupriet A, Collignon A, Barc M, Bourlioux P, Karjalainen T. GroEL (Hsp60) of Clostridium difficile is involved in cell adherence. Microbiology 2001; 147:87-96; PMID:11160803
26. Tasteyre A, Barc MC, Collignon A, Boureau H, Karjalainen T. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun 2001; 69:7937-40; PMID:11705981; http://dx.doi.org/10.1128/IAI.69. 12.7937-7940.2001
27. Elliott B, Chang BJ, Golledge CL, Riley TV. Clostridium difficile-associated diarrhoea. Intern Med J 2007; 37:561-8; PMID:17640189; http://dx.doi.org/10.1111/j.1445-5994.2007.01403.x
28. Kelly CP, Pothoulakis C, La Mont JT. Clostridium difficile colitis. New Engl J Med 1994; 330:257-62; PMID:8043060; http://dx.doi.org/10.1056/NEJM199401273300406
29. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18:247-63; PMID:15831824; http://dx.doi.org/10.1128/CMR.18.2.247-263.2005
30. Jank T, Aktories K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 2008; 16:222-9; PMID:18394902; http://dx.doi.org/10.1016/j.tim.2008.01.011
31. Pruitt RN, Lacy DB. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol 2012; 2:28; PMID:22919620; http://dx.doi.org/10.3389/fcimb.2012.00028
32. Zhang Y, Shi L, Li S, Yang Z, Standley C, Yang Z, Zhu Ge R, Savidge T, Wang X, Feng H. A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity. PloS One 2013; 8:e58634; PMID:23484044; http://dx.doi.org/10.1371/journal.pone.0058634
33. Reineke J, Tenzer S, Rupnik M, Koschinski A, Hasselmayer O, Schrattenholz A, Schild H, von Eichel-Streiber C. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 2007; 446:415-9; PMID:17334356; http://dx.doi.org/10.1038/nature05622
34. Greco A, Ho JG, Lin SJ, Palcic MM, Rupnik M, Ng KK. Carbohydrate recognition by Clostridium difficile toxin A. Nat Struct Mol Biol 2006; 13:460-1; PMID:16622409; http://dx.doi.org/10.1038/nsmb1084
35. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995; 375:500-3; PMID:7777059; http://dx.doi.org/10.1038/375500a0
36. Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun 2012; 4:149-58; PMID:22237401; http://dx.doi.org/10.1159/000332946
37. Geric B, Johnson S, Gerding DN, Grabnar M, Rupnik M. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol 2003; 41:5227-32; PMID:14605169; http://dx.doi.org/10.1128/JCM.41.11.5227-5232.2003
38. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186:307-12; PMID:10802189; http://dx.doi.org/10.1111/j.1574-6968.2000.tb09122.x
39. Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev: MMBR 2004; 68:373-402, table of contents; PMID:15353562; http://dx.doi.org/10.1128/MMBR.68.3.373-402.2004
40. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004; 42:1933-9; PMID:15131151; http://dx.doi.org/10.1128/JCM. 42.5.1933-1939.2004
41. Kuijper EJ, Coignard B, Tull P, difficile ESGfC, States EUM, European Centre for Disease P, EU Member States, European Centre for Disease Prevention and Control. Emergence of Clostridium difficileassociated disease in North America and Europe. Clin Microbiol Infect: Off Pub Eur Soc Clin Microbiol Infect Dis 2006; 12 Suppl 6:2-18; PMID:16965399; http://dx.doi.org/10.1111/j.1469-0691.2006.01580.x
42. See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, Holzbauer S, Dunn J, Farley MM, Lyons C, et al. NAP1 strain type predicts outcomes from clostridium difficile infection. Clin Infect Dis: Off Pub Infect Dis Soc Am 2014; 58:1394-400; PMID:24604900; http://dx.doi.org/10.1093/cid/ciu125
43. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes 2010; 1:58-64; PMID:20664812; http://dx.doi.org/10.4161/gmic.1.1.10768
44. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr., Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. New Engl J Med 2005; 353:2433-41; PMID:16322603; http://dx.doi.org/10.1056/NEJMoa051590
45. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ: Can Med Assoc J = J de l'Assoc Med Can 2004; 171:466-72; PMID:15337727; http://dx. doi.org/10.1503/cmaj.1041104
46. Tickler IA, Goering RV, Whitmore JD, Lynn AN, Persing DH, Tenover FC, Healthcare Associated Infection Consortium. Strain types and antimicrobial resistance patterns of clostridium difficile isolates from the United States: 2011-2013. Antimicrob Agents Chemoth 2014; 58:4214-8; PMID:24752264; http://dx.doi.org/10.1128/AAC.02775-13
47. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis: Off Pub Infect Dis Soc Am 2006; 42:758-64; PMID:16477549; http://dx.doi.org/10.1086/501126
48. Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis: Off Pub Infect Dis Soc Am 2011; 52:1451-7; PMID:21628487; http://dx.doi.org/10.1093/cid/cir201
49. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent clostridium difficile infection: a decision analysis. Clin Infect Dis: Off Pub Infect Dis Soc Am 2014; 58:1507-14; PMID:24692533; http://dx.doi.org/10.1093/cid/ciu128
50. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014; 42:43-59; PMID:23839210; http://dx.doi.org/10.1007/s15010-013-0496-x
51. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75; PMID:12135033; http://dx.doi.org/10.1111/j.1572-0241.2002.05839.x
52. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13:97-101; PMID:4030111; http://dx.doi.org/10.1007/BF01642866
53. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992; 166:1287-94; PMID:1431247; http://dx.doi.org/10.1093/infdis/166.6.1287
54. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis: Off Pub Infect Dis Soc Am 1993; 16 Suppl 4:S239-44; PMID:8324125; http://dx.doi.org/10.1093/clinids/16.Supplement-4.S239
55. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384-9; PMID:8300199
56. Galdys AL, Curry SR, Harrison LH. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. Expert Rev Anti-Infect Ther 2014; 12:967-80; PMID:24848084; http://dx. doi.org/10.1586/14787210.2014.920252
57. Kyne L, Warny M, Qamar A, Kelly CP. High antitoxin A antibody levels are associated with protection against recurrent Clostridium difficile diarrhea. Gastroenterology 2000; 118:A885-A; ; http://dx.doi.org/10.1016/S0016-5085(00)85679-6
58. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93; PMID:11213096; http://dx.doi.org/10.1016/S0140-6736(00)03592-3
59. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28:965-9; PMID:19941990; http://dx.doi.org/10.1016/j.vaccine.2009.10.144
60. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. New Engl J Med 2000; 342:390-7; PMID:10666429; http://dx.doi.org/10.1056/NEJM200002103420604
61. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, Cosentini E, Feil W, Schiessel R, La Mont JT, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995; 95:2004-11; PMID:7738167; http://dx.doi.org/10.1172/JCI117885
62. Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis: IJID: Off Pub Int Soc Infect Dis 2007; 11:5-10; PMID:16857405; http://dx.doi.org/10.1016/j.ijid. 2006.04.003
63. Johnson S, Kent SA, O'Leary KJ, Merrigan MM, Sambol SP, Peterson LR, Gerding DN. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001; 135:434-8; PMID:11560456; http://dx.doi.org/10.7326/0003-4819-135-6-200109180-00012
64. Rebeaud F, Bachmann MF. Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines 2012; 11:469-79; PMID:22551032; http://dx. doi.org/10.1586/erv.12.18
65. Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick EF, O'Keane JC, Keates S, La Mont JT. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemoth 1996; 40:373-9; PMID:8834883
66. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991; 59:2215-8; PMID:2037383
67. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66:2018-25; PMID:9573084
68. Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med: Off Pub Soc Hosp Med 2010; 5:E1-9; PMID:20063275; http://dx.doi.org/10.1002/jhm.542
69. Aldeyab MA, McElnay JC, Scott MG, Davies E, Edwards C, Darwish Elhajji FW, Conlon G, Magee FA, Barr PJ, Kearney MP. An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of Clostridium difficile infections. Infect Control Hosp Epidemiol: Off J Soc Hosp Epidemiologists Am 2011; 32:631-3; PMID:21558782; http://dx.doi.org/10.1086/660203
70. Hassoun A, Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am J Geriat Pharmacother 2007; 5:48-51; PMID:17608247; http://dx.doi.org/10.1016/j. amjopharm.2007.03.001
71. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemoth 2004; 53:882-4; PMID:15073160; http://dx.doi.org/10.1093/jac/dkh176
72. Tjellstrom B, Stenhammar L, Eriksson S, Magnusson KE. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 1993; 341:701-2; PMID:8095616; http://dx.doi.org/10.1016/0140-6736(93)90477-X
73. Kelly CP, Chetham S, Keates S, Bostwick EF, Roush AM, Castagliuolo I, La Mont JT, Pothoulakis C. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemoth 1997; 41:236-41; PMID:9021173
74. van Dissel JT, de Groot N, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P, van 't Wout J. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005; 54:197-205; PMID:15673517; http://dx.doi.org/10.1099/jmm.0.45773-0
75. Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007; 56:888-9; PMID:17519495; http://dx.doi.org/10.1136/gut.2006.119016
76. Lyerly DM, Phelps CJ, Toth J, Wilkins TD. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun 1986; 54:70-6; PMID:2428753
77. Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991; 59:1192-5; PMID:1900059
78. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006; 74:6339-47; PMID:16966409; http://dx.doi.org/10.1128/IAI.00982-06
79. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl J Med 2010; 362:197-205; PMID:20089970; http://dx.doi.org/10.1056/NEJMoa0907635
80. Dawson AE, Shumak SL, Redelmeier DA. Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl J Med 2010; 362:1445; author reply -6; PMID:20397290
81. Hussack G, Tanha J. Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins 2010; 2:998-1018; PMID:22069622; http://dx.doi.org/10.3390/toxins2050998
82. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012; 30:4307-9; PMID:22682287; http://dx.doi.org/10.1016/j. vaccine.2012.01.056
83. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR. Preformulation studies of Clostridium difficile toxoids A and B. J Pharm Sci 2008; 97:4194-207; PMID:18228584; http://dx.doi.org/10.1002/jps.21300
84. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764-70; PMID:15765411; http://dx.doi.org/10.1053/j.gastro.2004.11.004
85. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608-10; PMID:12595488; http://dx.doi.org/10.1128/IAI.71.3.1608-1610.2003
86. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W, Jr., Nichols R, Edelman R, Bridwell M, Monath TP. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69:988-95; PMID:11159994; http://dx.doi.org/10.1128/IAI.69. 2.988-995.2001
87. Donald RG, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 2013; 159:1254-66; PMID:23629868; http://dx.doi.org/10.1099/mic.0.066712-0
88. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 1999; 67:2145-52; PMID:10225867
89. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 2012; 30:4249-58; PMID:22537987; http://dx.doi.org/10.1016/j. vaccine.2012.04.045
90. Colenutt C, Cutting SM. Use of Bacillus subtilis PXN21 spores for suppression of Clostridium difficile infection symptoms in a murine model. FEMS Microbiol Lett 2014; PMID:24828432
91. Stiles BG, Wigelsworth DJ, Popoff MR, Barth H. Clostridial binary toxins: iota and C2 family portraits. Front Cell Infect Microbiol 2011; 1:11; PMID:22919577; http://dx.doi.org/10.3389/fcimb. 2011.00011
92. Stewart DB, Berg A, Hegarty J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastr Surg: Off J Soc Surg Aliment Tract 2013; 17:118-24; discussion p 24-5; PMID:23086451; http://dx.doi.org/10.1007/s11605-012-2056-6
93. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. New Engl J Med 1989; 320:204-10; PMID:2911306; http://dx.doi.org/10.1056/NEJM198901263200402
94. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis: Off Pub Infect Dis Soc Am 2007; 45:992-8; PMID:17879913; http://dx.doi.org/10.1086/521854
95. Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 1987; 55:2984-92; PMID:3679541
96. Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP. The ClosTron: a universal gene knockout system for the genus Clostridium. J Microbiol Methods 2007; 70:452-64; PMID:17658189; http://dx.doi.org/10.1016/j.mimet.2007.05.021
97. Wright A, Wait R, Begum S, Crossett B, Nagy J, Brown K, Fairweather N. Proteomic analysis of cell surface proteins from Clostridium difficile. Proteomics 2005; 5:2443-52; PMID:15887182; http://dx. doi.org/10.1002/pmic.200401179
98. Fagan RP, Albesa-Jove D, Qazi O, Svergun DI, Brown KA, Fairweather NF. Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol 2009; 71:1308-22; PMID:19183279; http://dx.doi.org/10.1111/j.1365-2958.2009.06603.x
99. Ni Eidhin DB, O'Brien JB, McCabe MS, Athie-Morales V, Kelleher DP. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 2008; 52:207-18; PMID:18093141; http://dx.doi.org/10.1111/j.1574-695X.2007.00363.x
100. Tasteyre A, Karjalainen T, Avesani V, Delmee M, Collignon A, Bourlioux P, Barc MC. Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2001; 39:1178-83; PMID:11230454; http://dx.doi.org/10.1128/JCM.39.3.1178-1183.2001
101. Tasteyre A, Karjalainen T, Avesani V, Delmee M, Collignon A, Bourlioux P, Barc MC. Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2000; 38:3179-86; PMID:10970353
102. Pechine S, Gleizes A, Janoir C, Gorges-Kergot R, Barc MC, Delmee M, Collignon A. Immunological properties of surface proteins of Clostridium difficile. J Med Microbiol 2005; 54:193-6; PMID:15673516; http://dx.doi.org/10.1099/jmm.0.45800-0
103. Pechine S, Janoir C, Boureau H, Gleizes A, Tsapis N, Hoys S, Fattal E, Collignon A. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 2007; 25:3946-54; PMID:17433506; http://dx.doi.org/10.1016/j.vaccine.2007.02.055
104. Ganeshapillai J, Vinogradov E, Rousseau J, Weese JS, Monteiro MA. Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units. Carbohyd Res 2008; 343:703-10; PMID:18237724; http://dx.doi.org/10.1016/j.carres.2008.01.002
105. Oberli MA, Hecht ML, Bindschadler P, Adibekian A, Adam T, Seeberger PH. A possible oligosaccharideconjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 2011; 18:580-8; PMID:21609839; http://dx.doi.org/10.1016/j.chembiol.2011.03.009
106. Monteiro MA, Ma Z, Bertolo L, Jiao Y, Arroyo L, Hodgins D, Mallozzi M, Vedantam G, Sagermann M, Sundsmo J, et al. Carbohydrate-based Clostridium difficile vaccines. Expert Rev Vaccines 2013; 12:421-31; PMID:23560922; http://dx.doi.org/10.1586/erv.13.9
107. Tedesco FJ, Stanley RJ, Alpers DH. Diagnostic features of clindamycin-associated pseudomembranous colitis. New Engl J Med 1974; 290:841-3; PMID:4855527; http://dx.doi.org/10.1056/NEJM197404112901508
108. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. New Engl J Med 1978; 298:531-4; PMID:625309; http://dx.doi.org/10.1056/NEJM197803092981003
109. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012; 30:2245-9; PMID:22306375; http://dx.doi.org/10.1016/j. vaccine.2012.01.065
110. Pechine S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol 2005; 43:5018-25; PMID:16207956; http://dx.doi.org/10.1128/JCM.43.10.5018-5025.2005